


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1. (Previously presented) A method of modulating an endothelial gene differentiation-1 (“Edg-1”) receptor mediated for vasoconstriction, comprising contacting a cell expressing the Edg-1 receptor with an amount of a non-phospholipid modulator of the Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated for vasoconstriction, wherein said modulator is a compound of Formula (Ia):




(Ia)

- or a pharmaceutically acceptable solvate or hydrate thereof, wherein
- n is a member selected from the integers 0 to 5;
- R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;
- each R^2 , R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted

21 acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio,
22 alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl,
23 alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted
24 arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl,
25 arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy,
26 carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl,
27 cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted
28 dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted
29 heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and
30 each R⁴ is a member independently selected from the group consisting of hydrogen, halo,
31 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
32 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
33 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
34 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
35 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted
36 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano,
37 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
38 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted
39 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
40 heteroalkyl, hydroxyl, nitro and thio.

- 1 2. (Previously presented) A method of modulating an Edg-1 receptor mediated for
2 vasoconstriction in a subject, comprising administering to the subject a therapeutically
3 effective amount of a non-phospholipid modulator of the Edg-1 receptor, wherein said
4 modulator is a compound of Formula (Ia):



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein:

n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2 , R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and

29 each R⁴ is a member independently selected from the group consisting of hydrogen, halo,
30 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
31 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
32 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
33 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
34 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted
35 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano,
36 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
37 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted
38 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
39 heteroalkyl, hydroxyl, nitro and thio.

1 3. (Canceled)

1 4. (Canceled)

1 5. (Canceled)

1 6. (Canceled)

1 7. (Canceled)

1 8. (Canceled)

1 9. (Canceled)

1 10. (Canceled)

1 11. (Canceled)

1 12. (Canceled)


1 13. (Canceled)

- 1 **14.** (Canceled)
- 1 **15.** (Canceled)
- 1 **16.** (Canceled)
- 1 **17.** (Canceled)
- 1 **18.** (Canceled)
- 1 **19.** (Canceled)
- 1 **20.** (Canceled)
- 1 **21.** (Canceled)
- 1 **22.** (Canceled)
- 1 **23.** (Canceled)
- 1 **24.** (Canceled)
- 1 **25.** (Canceled)
- 1 **26.** (Canceled)
- 1 **27.** (Canceled)
- 1 **28.** (Canceled)
- 1 **29.** (Canceled)
- 1 **30.** (Canceled)
- 1 **31.** (Canceled)

32. (Canceled)

33. (Canceled)

34. (Previously presented) A method for treating vasoconstriction in cerebral arteries in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a compound of Formula (Ia), wherein said compound of Formula (Ia) is:



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;


R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2 , R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio,

22 substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted
23 alkoxycarbonyl, alkylaryl amino, substituted alkylaryl amino, arylalkyloxy,
24 substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted
25 arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted
26 arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl,
27 substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
28 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted
29 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
30 heteroalkyl, hydroxyl, nitro and thio; and

31 each R⁴ is a member independently selected from the group consisting of hydrogen, halo,
32 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
33 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
34 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylaryl amino,
35 substituted alkylaryl amino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
36 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted
37 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano,
38 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
39 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted
40 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
41 heteroalkyl, hydroxyl, nitro and thio.

1 **35.** (Previously presented) A method for treating vasoconstriction in a subject in need of such
2 treatment, said method comprising administering to said subject a therapeutically
3 effective amount of a compound of Formula (Ia), wherein said compound of Formula (Ia)
4 is:



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein


n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2 , R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted

heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio;
each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio;
and one or more antagonists of an Edg receptor.

36. (Previously presented) A method for treating in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a compound of Formula (Ia), wherein said compound of Formula (Ia) is:



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted


alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylaryl amino, substituted alkylaryl amino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;


each R^2 , R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylaryl amino, substituted alkylaryl amino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio;

each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylaryl amino, substituted alkylaryl amino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted

39 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
40 heteroalkyl, hydroxyl, nitro and thio;
41 and one or more drugs useful in treating vasoconstriction.

1 **37.** (Previously presented) The method of Claim 1 or 2, wherein the modulator is a
2 compound of a formula that is selected from:





1 **38.** (Canceled)

1 **39.** (Canceled)

1 **40.** (Canceled)

1 **41.** (Canceled)

1 **42.** (Canceled)

1 **43.** (Canceled)

1 **44.** (Canceled)

1 **45.** (Canceled)

1 **46.** (Canceled)


1 **47.** (Canceled)

1 **48.** (Canceled)

1 **49.** (Canceled)

1 **50.** (Canceled)

1 **51.** (Previously presented) A method of treating vasoconstriction in a patient comprising:
2 administering to the patient a therapeutically effective amount of a modulator of an Edg-1
3 receptor wherein the modulator is a compound of Formula (Ib) is:




(Ib)

4
5 or a pharmaceutically acceptable solvate or hydrate thereof, wherein
6 n is a member selected from the integers 0 to 5;
7 R^{11} is an aryl group;
8 each R^2 and R^4 is a member independently selected from the group consisting of
9 hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino,
10 substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted
11 alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl,
12 alkylaryl amino, substituted alkylaryl amino, arylalkyloxy, substituted

13 arylalkyloxy, amino, aryl, substituted aryl, arylalicyl, substituted arylalkyl,
14 arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy,
15 carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl,
16 cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted
17 dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted
18 heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

1 **52.** (Previously presented) The method of claim **51**, wherein said aryl group in R^{11} is a
2 heteroaryl group.

1 **53.** (Previously presented) The method of claim **52**, wherein said compound has the formula:



1 **54.** (Previously presented) The method of claim **53**, wherein R^2 is a substituted alkyl group.


1 **55.** (Previously presented) The method of claim **54**, wherein R^2 is said substituted alkyl
2 group is $-CF_3$.

1 **56.** (Previously presented) The method of claim **55**, wherein n is 1.

1 **57.** (Previously presented) The method of claim **56**, wherein R^4 is a halo group.

1 **58.** (Previously presented) The method of claim **57**, wherein said halo group is chlorine.

2 **59.** (Previously presented) A method of treating vasoconstriction in a patient comprising:
3 administering to the patient a therapeutically effective amount of a modulator of an Edg-1
4 receptor wherein the modulator is a compound of Formula (Ic):



(Ic)

n is a member selected from the integers 0 to 5;
each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

60. (Previously presented) The method of claim **59**, wherein n is 1.

61. (Previously presented) The method of claim **60**, wherein R^4 is a halo group.

62. (Previously presented) The method of claim **61**, wherein said halo group is chlorine.

63. (Canceled)

64. (Canceled)